Select country set
language
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

hsa-miR-122-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RDM0045H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Tissue extract, Cell culture lysate, Whole blood

Sample Requirements

10 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

25 – 0.78 amol/μl

Limit of Detection

0.26 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 7.3%

Inter-assay (Run-to-Run)

n = 5,
CV = 5.6%

Spiking Recovery

96.2%

Dilution Linearity

102.3%

Specificity

Crossreactivity with the miRNA family members exhibiting high sequence identity cannot be excluded.

Note

Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.


Product Manual: miREIA - microRNA enzyme immunoassay

 

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-122-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Cardiovascular disease, Oncology, Others

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in the pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

Among different types of miRNAs in liver, miR-122 is the most abundant and tissue-specific miRNA. Levels of hsa-miR-122-5p and hsa-miR-885-5p were up-regulated in individuals with fatty liver (FL). Together hsa-miR-122-5p and has-miR-885-5p slightly improved the detection of FL beyond established risk factors. These miRNAs may be associated with FL formation through the regulation of lipoprotein metabolism as hsa-miR-122-5p levels correlated with small VLDL, LDL, and large LDL lipoprotein subclass components, while hsa-miR-885-5p levels correlated inversely with XL HDL cholesterol levels. hsa-miR-122 exhibited significantly different expression levels between fibrosis stages. hsa-miR-122-5p, hsa-miR-146a, hsa-miR-29c and hsa-miR-223 were positively correlated with fibrosis stage. On the contrary, hsa-miR-122-5p and hsa-miR-381-3p were negatively correlated with alanine aminotransferase, aspartate transaminase and HBV viral DNA load. Liver biopsies showed that miR-122 is up-regulated in hepatosteatosis. Surprisingly, the protein and RNA level of identified targets of miR-122 are also up-regulated in clinical samples, probably as a disproportionate feedback response to the high level of miR-122. miR-122 might regulate TAG metabolism by targeting key enzymes that are involved in its production pathway. A systematic computational analysis of putative targets of miR-122 identified CTDNEP1 and LPIN1 genes in the triacylglycerol (TAG) pathway.

miR-122-5p overexpression significantly restrained the proliferation, migration and invasion of hepatocellular carcinoma (HCC) cells. The expression levels of miR-122-5p were significantly higher in alpha-fetoprotein (AFP)-producing gastric cancer (AFPGC) patients than in non-AFPGC patients. In tissue samples, miR-122-5p expression level tended to be lower in non-AFPGC tissue than the normal gastric mucosa. Conversely, miR-122-5p expression level was significantly higher in AFPGC tissue than both normal gastric mucosa and non-AFPGC tissue samples. Plasma miR-122-5p expression levels were also significantly higher in AFPGC patients than the health volunteers and non-AFPGC patients and were strongly correlated with plasma AFP levels. Moreover, the correlation of miR-122-5p expression in tissue samples with malignant potential was stronger than that of plasma AFP level in AFPGC patients. In contrast, no correlation was found between miR-122-5p expression levels and liver metastasis in non-AFPGC patients.

In a study of hospital patients who suffered out-of-hospital cardiac arrest, miR-122-5p demonstrated a marked acute increase in plasma and was independently associated with lactate and bystander resuscitation. However, miR-122-5p at admission was not associated with all-cause mortality or shock at admission. Plasma miR-122-5p at admission after OHCA was 400-fold elevated compared to controls. Event-free survival was significantly worse in patients (patients treated with primary angioplasty) with a higher miR-122-5p/133b ratio, having almost a 9-fold higher risk of death or myocardial infarction and a 4-fold higher risk of adverse cardiovascular events. The miR-122-5p/133b ratio is a new prognostic biomarker for the early identification of STEMI patients at a higher risk of developing major adverse events after undergoing primary percutaneous coronary intervention. Plasma miR-122-5p levels were significantly elevated in AMI patients, while plasma miR-22-5p levels were significantly decreased. In addition, significant correlations between miR-22-5p and miR-122-5p, miR-122-5p and creatine kinase isoenzyme (CK-MB) were detected.

Summary References (8)

References to miR-122-5p

  • Cortez-Dias N, Costa MC, Carrilho-Ferreira P, Silva D, Jorge C, Calisto C, Pessoa T, Robalo Martins S, de Sousa JC, da Silva PC, Fiúza M, Diogo AN, Pinto FJ, Enguita FJ. Circulating miR-122-5p/miR-133b Ratio Is a Specific Early Prognostic Biomarker in Acute Myocardial Infarction. Circ J. 2016 Sep 23;80(10):2183-91. doi: 10.1253/circj.CJ-16-0568. Epub 2016 Sep 2. Erratum in: Circ J. 2017;81(4):613. PMID: 27593229. See more on PubMed
  • Gilje P, Frydland M, Bro-Jeppesen J, Dankiewicz J, Friberg H, Rundgren M, Devaux Y, Stammet P, Al-Mashat M, Jögi J, Kjaergaard J, Hassager C, Erlinge D. The association between plasma miR-122-5p release pattern at admission and all- cause mortality or shock after out-of-hospital cardiac arrest. Biomarkers. 2019 Feb;24(1):29-35. doi: 10.1080/1354750X.2018.1499804. Epub 2018 Aug 23. PMID: 30015516. See more on PubMed
  • Maruyama S, Furuya S, Shiraishi K, Shimizu H, Akaike H, Hosomura N, Kawaguchi Y, Amemiya H, Kawaida H, Sudo M, Inoue S, Kono H, Ichikawa D. miR-122-5p as a novel biomarker for alpha-fetoprotein-producing gastric cancer. World J Gastrointest Oncol. 2018 Oct 15;10(10):344-350. doi: 10.4251/wjgo.v10.i10.344. PMID: 30364858; PMCID: PMC6198302. See more on PubMed
  • Naderi M, Pazouki A, Arefian E, Hashemi SM, Jamshidi-Adegani F, Gholamalamdari O, Soudi S, Azadmanesh K, Mirab Samiee S, Merat S, Gholami Fesharaki M, Mondanizadeh M, Vasei M, Soleimani M. Two Triacylglycerol Pathway Genes, CTDNEP1 and LPIN1, are Down-Regulated by hsa-miR-122-5p in Hepatocytes. Arch Iran Med. 2017 Mar;20(3):165-171. PMID: 28287811. See more on PubMed
  • Raitoharju E, Seppälä I, Lyytikäinen LP, Viikari J, Ala-Korpela M, Soininen P, Kangas AJ, Waldenberger M, Klopp N, Illig T, Leiviskä J, Loo BM, Oksala N, Kähönen M, Hutri-Kähönen N, Laaksonen R, Raitakari O, Lehtimäki T. Blood hsa- miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism-The Young Finns Study. Sci Rep. 2016 Dec 5;6:38262. doi: 10.1038/srep38262. PMID: 27917915; PMCID: PMC5137183. See more on PubMed
  • Wang TZ, Lin DD, Jin BX, Sun XY, Li N. Plasma microRNA: A novel non-invasive biomarker for HBV-associated liver fibrosis staging. Exp Ther Med. 2019 Mar;17(3):1919-1929. doi: 10.3892/etm.2018.7117. Epub 2018 Dec 19. PMID: 30783469; PMCID: PMC6364194. See more on PubMed
  • Wang Y, Chang W, Zhang Y, Zhang L, Ding H, Qi H, Xue S, Yu H, Hu L, Liu D, Zhu W, Wang Y, Li P. Circulating miR-22-5p and miR-122-5p are promising novel biomarkers for diagnosis of acute myocardial infarction. J Cell Physiol. 2019 Apr;234(4):4778-4786. doi: 10.1002/jcp.27274. Epub 2018 Sep 7. PMID: 30256407. See more on PubMed
  • Zhang L, Wang Y, Sun J, Ma H, Guo C. LINC00205 promotes proliferation, migration and invasion of HCC cells by targeting miR-122-5p. Pathol Res Pract. 2019 Sep;215(9):152515. doi: 10.1016/j.prp.2019.152515. Epub 2019 Jun 26. PMID: 31272761. See more on PubMed
Related Products Docs